Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omadacycline vs Moxifloxacin in CABP
NCT04779242Phase 3Completed
- Sponsor
- Paratek Pharmaceuticals
- Start
- Feb 2021
- Primary completion
- Mar 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of omadacycline in community-acquired bacterial pneumonia (CAP), sponsored by Paratek Pharmaceuticals. Started Feb 2021; status: completed.
02
Drugs
omadacycline
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT04779242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04779242.